Academic Journal
Προβολή σε EDS

Assessing the abuse liability of U.S. Food and Drug Administration-authorized electronic nicotine delivery systems: Impact of nicotine flux, flavor, and menthol cigarette smoking status.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Assessing the abuse liability of U.S. Food and Drug Administration-authorized electronic nicotine delivery systems: Impact of nicotine flux, flavor, and menthol cigarette smoking status.
Συγγραφείς: Ogunleye EO; Department of Psychology, Virginia Commonwealth University., Bono RS; Department of Health Policy, School of Public Health, Virginia Commonwealth University., Imran R; Department of Psychology, Virginia Commonwealth University., Gaitan N; Department of Psychology, Virginia Commonwealth University., Lipato T; Department of Internal Medicine, School of Medicine, Virginia Commonwealth University., Barnes AJ; Department of Health Policy, School of Public Health, Virginia Commonwealth University., Cobb CO; Department of Psychology, Virginia Commonwealth University.
Πηγή: Experimental and clinical psychopharmacology [Exp Clin Psychopharmacol] 2026 Aug; Vol. 34 (4), pp. 374-386. Date of Electronic Publication: 2026 Jul 13.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: American Psychological Association Country of Publication: United States NLM ID: 9419066 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-2293 (Electronic) Linking ISSN: 10641297 NLM ISO Abbreviation: Exp Clin Psychopharmacol Subsets: MEDLINE
Imprint Name(s): Original Publication: Washington, DC : American Psychological Association, c1993-
Ιατρικοί όροι (MeSH): Electronic Nicotine Delivery Systems*/economics , Menthol*/administration & dosage , Nicotine*/administration & dosage , Flavoring Agents*/administration & dosage , Cigarette Smoking*, Humans ; United States ; Adult ; United States Food and Drug Administration ; Female ; Male ; Young Adult ; Middle Aged
Περίληψη: The U.S. Food and Drug Administration has authorized 41 electronic nicotine delivery systems (ENDS) that meet its public health standard. This clinical lab study utilized behavioral economic and subjective measures to index the abuse liability of currently authorized ENDS that varied in nicotine flux (i.e., μg nicotine/s) and flavor among adults who smoke cigarettes. Using a Latin square-ordered, within-subject design, adults who smoke cigarettes (n = 30; 20 menthol preferring [MP]) completed four sessions: one with own-brand cigarettes and three with tobacco and menthol flavors of three NJOY-branded ENDS: 2.4% nicotine (58 μg/s flux), 5% nicotine (118-123 μg/s flux), 6% nicotine (61-65 μg/s flux). Outcomes included behavioral economic indices (e.g., price sensitivity) and subjective measures (e.g., product acceptability). Mixed analysis of variance was used to examine the effects of ENDS nicotine flux, flavor, and MP. MP participants were less price sensitive than those who smoked nonmenthol, particularly for menthol-flavored ENDS. Those who smoked nonmenthol were less price sensitive for tobacco-flavored versus menthol-flavored ENDS. MP participants substituted all ENDS for own-brand cigarettes, while those who smoked nonmenthol only substituted with lower flux tobacco-flavored and higher flux menthol-flavored ENDS. Greater positive ratings on some acceptability measures were observed for menthol-flavored than tobacco-flavored ENDS. Those who smoked nonmenthol reported greater aversive ENDS-related sensory effects than MP participants. Menthol flavoring in ENDS increased some abuse liability measures, particularly product acceptability. ENDS abuse liability and substitution potential also varied by MP. Lower flux tobacco and higher flux menthol ENDS may support switching. Findings support further investigation on menthol-flavored, higher flux ENDS for public health benefit. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
References: Physiol Behav. 2004 Aug;82(1):109-14. (PMID: 15234598)
Nicotine Tob Res. 2020 Oct 8;22(10):1676-1684. (PMID: 31867627)
Exp Clin Psychopharmacol. 2006 May;14(2):121-35. (PMID: 16756416)
Addict Biol. 2019 Mar;24(2):303-314. (PMID: 29314376)
Exp Clin Psychopharmacol. 2015 Oct;23(5):377-86. (PMID: 26147181)
Nicotine Tob Res. 2015 Mar;17(3):292-8. (PMID: 25168032)
Subst Use Misuse. 2025;60(3):311-318. (PMID: 39491336)
Drug Alcohol Depend. 2022 Sep 1;238:109580. (PMID: 35908345)
J Pharm Pharmacol. 1994 Aug;46(8):618-30. (PMID: 7529306)
Drug Alcohol Depend. 2024 May 1;258:111279. (PMID: 38614020)
Nicotine Tob Res. 2014 Sep;16 Suppl 3:S190-201. (PMID: 25118226)
JAMA Netw Open. 2024 Aug 1;7(8):e2426702. (PMID: 39120901)
Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3241-62. (PMID: 19959676)
Nicotine Tob Res. 2019 Oct 26;21(11):1556-1564. (PMID: 29301008)
Exp Clin Psychopharmacol. 2023 Oct;31(5):895-901. (PMID: 36480388)
Psychopharmacology (Berl). 1992;106(3):421-7. (PMID: 1570391)
Nicotine Tob Res. 2022 Aug 6;24(9):1332-1343. (PMID: 35305014)
Drug Alcohol Depend. 2019 Oct 1;203:99-106. (PMID: 31434028)
Drug Alcohol Depend. 2025 Jan 1;266:112508. (PMID: 39657440)
Nicotine Tob Res. 2010 Dec;12 Suppl 2:S110-6. (PMID: 21177367)
Psychopharmacology (Berl). 2020 Feb;237(2):491-502. (PMID: 31773209)
Chem Senses. 2009 Nov;34(9):739-51. (PMID: 19833660)
Arch Gen Psychiatry. 1986 Mar;43(3):289-94. (PMID: 3954551)
Addiction. 2020 Dec;115(12):2357-2368. (PMID: 32285978)
Psychopharmacology (Berl). 2000 Dec;153(1):44-56. (PMID: 11255928)
Drug Alcohol Depend. 2022 Aug 1;237:109516. (PMID: 35679691)
Prev Med. 2022 Dec;165(Pt B):107122. (PMID: 35787842)
Br J Addict. 1991 Sep;86(9):1119-27. (PMID: 1932883)
J Psychopharmacol. 2017 Jul;31(7):851-860. (PMID: 28612651)
Nicotine Tob Res. 2015 May;17(5):592-8. (PMID: 25548256)
Exp Clin Psychopharmacol. 2021 Aug;29(4):355-365. (PMID: 32297782)
Nicotine Tob Res. 2015 Feb;17(2):150-7. (PMID: 25187061)
Tob Control. 2022 Jan 27;:. (PMID: 35086911)
Exp Clin Psychopharmacol. 2024 Oct;32(5):604-614. (PMID: 38815113)
Psychopharmacology (Berl). 1994 Jun;115(1-2):9-14. (PMID: 7862918)
Exp Clin Psychopharmacol. 2023 Apr;31(2):443-454. (PMID: 35696157)
Nicotine Tob Res. 2023 Feb 9;25(3):412-420. (PMID: 35965260)
Addiction. 2012 Jul;107(7):1330-8. (PMID: 22471735)
Drug Alcohol Depend. 2016 Sep 01;166:263-7. (PMID: 27426010)
Pharmacol Biochem Behav. 1993 Jun;45(2):375-81. (PMID: 8327544)
Nicotine Tob Res. 2020 Apr 21;22(5):771-781. (PMID: 30995302)
Exp Clin Psychopharmacol. 2022 Feb;30(1):113-119. (PMID: 33001692)
Yale J Biol Med. 2015 Sep 03;88(3):279-87. (PMID: 26339211)
Nicotine Tob Res. 2025 Jun 23;27(7):1177-1185. (PMID: 39290086)
Exp Clin Psychopharmacol. 2022 Dec;30(6):973-982. (PMID: 34647773)
Aerosol Sci Technol. 2017;51(1):1-11. (PMID: 28706340)
Nicotine Tob Res. 2025 Aug 22;27(9):1657-1661. (PMID: 40056399)
Drug Alcohol Depend. 2024 Mar 1;256:111110. (PMID: 38359606)
Tob Control. 2016 Nov;25(Suppl 2):ii67-ii72. (PMID: 27633766)
Drug Alcohol Depend. 2017 Nov 1;180:193-199. (PMID: 28915478)
Nicotine Tob Res. 2015 Feb;17(2):158-62. (PMID: 25180079)
Nicotine Tob Res. 2022 Jan 1;24(1):20-27. (PMID: 34405884)
Tob Control. 2011 May;20 Suppl 2:ii29-36. (PMID: 21504929)
Nicotine Tob Res. 2016 Jul;18(7):1588-95. (PMID: 26783293)
Grant Information: U54 DA036105 United States DA NIDA NIH HHS; UM1 TR004360 United States TR NCATS NIH HHS; National Institutes of Health; National Institute on Drug Abuse; Food and Drug Administration; Center for Tobacco Products
Substance Nomenclature: 1490-04-6 (Menthol)
6M3C89ZY6R (Nicotine)
0 (Flavoring Agents)
Entry Date(s): Date Created: 20260713 Date Completed: 20260723 Latest Revision: 20260922
Update Code: 20260922
PubMed Central ID: PMC13367412
DOI: 10.1037/pha0000861
PMID: 42441607
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1936-2293
DOI:10.1037/pha0000861